- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01809886
Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial (SUGAPED-01)
Reversal With Sugammadex (BRIDION ®) From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial of Efficacy and Safety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Muscle relaxing facilitates endotracheal intubation and surgical access. Muscle relaxants have a long duration with the possibility of residual muscle relaxation after surgery (over 40% of patients), and ventilatory problems (hypoxia, hypercapnia, atelectasis, airway collapse) that raise postoperative morbidity and mortality.
All of these facts are accentuated in the pediatric patient due to the reduced airway caliber which tends lead to obstruction and bronchospasm. So far, the effect of muscle relaxants has only been partially reversed by anticholinesterase (neostigmine), which has the limitation of its short duration of action (8-9 minutes) and has many side effects (bradycardia, hypotension, increased salivation, vomiting, dyspnea and bronchoconstriction). It also needs to be combined with anticholinergic (atropine), which causes a dry mouth, blurred vision and tachycardia.
At present, the introduction of sugammadex (Bridion®), an antagonist of nondepolarizing the neuromuscular relaxant rocuronium, may lead to an extraordinary breakthrough. It is the only antagonist able to encapsulate and fully eliminate the muscle relaxant to avoid residual effects and respiratory complications. Muscle strength can be retrieved at any time, without waiting for relaxant metabolism (30 to 40 minutes) and without using the usual classical antidotes (neostigmine and atropine), which produce many undesirable effects that become more troublesome in the postoperatory phase. Sugammadex lacks intrinsic activity and is considered safe, without significant side effects and can be used in cardiovascular or respiratory diseases.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Mª Dolores Cárceles Barón
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children of both sexes,
- Aged between two and eleven years who have undergone surgery for procedures of short duration (less than one hour) and requiring muscle relaxation.
- Informed consent signed by parents or guardians
Exclusion Criteria:
- No signed informed consent by parent/guardian,
- Anticipated difficult airway,
- Neuromuscular disease,
- Liver and/or renal failure,
- Personal or family history of malignant hyperthermia,
- Previous allergic reaction to any anesthetic.
- Treated at the time of the study with aminoglycosides, magnesium, or anticonvulsants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sugammadex
50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation.
The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
|
50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation.
The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
|
Active Comparator: Neostigmina
50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation.
The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
|
50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation.
The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The time in seconds which has elapsed until a T4/T1 ratio >0,9.
Time Frame: After surgery (Up to 10 h)
|
After surgery (Up to 10 h)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Heart Rate (beats / min)
Time Frame: After surgery (Up to 10 h)
|
After surgery (Up to 10 h)
|
Systolic and Diastolic blood pressure (mm HG)
Time Frame: After surgery (up to 10 h)
|
After surgery (up to 10 h)
|
Arterial oxygen saturation (%)
Time Frame: After surgery (up to 10 h)
|
After surgery (up to 10 h)
|
Total dose of rocuronium (mg/kg)
Time Frame: After surgery (up to 10 h)
|
After surgery (up to 10 h)
|
Number of participants with at least One Adverse event (AE)
Time Frame: up to 24 h
|
up to 24 h
|
Time in seconds from the initial dose administered of rocuronium until the maximum block is achieved(Onset time)
Time Frame: During peri-anesthetic period (up to 10 h)
|
During peri-anesthetic period (up to 10 h)
|
The time in seconds which has elapsed until a T4/T1 >0,8 is achieved.
Time Frame: After surgery (up to 10 h)
|
After surgery (up to 10 h)
|
The time in seconds which has elapsed until a T4/T1 ratio >0,7
Time Frame: After surgery (up to 10 h)
|
After surgery (up to 10 h)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: MºDolores Cárceles Barón, MD,PhD, Hospital Universitario Virgen de la Arrixaca
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-PED-2010-01CT
- 2011-000401-50 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Blockade
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedNeuromuscular Blockade | Neuromuscular MonitoringItaly
-
Universitair Ziekenhuis BrusselUnknownNeuromuscular Blockade | Neuromuscular MonitoringBelgium
-
Central Hospital, Nancy, FranceNot yet recruitingComparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function (DECURAR-EMG)Neuromuscular BlockadeFrance
-
Vanderbilt University Medical CenterUniversity of Pittsburgh; The Cooper Health SystemRecruitingNeuromuscular BlockadeUnited States
-
Leiden University Medical CenterMerck Sharp & Dohme LLCCompletedNeuromuscular BlockadeNetherlands
-
Seoul National University Bundang HospitalCompleted
-
Poitiers University HospitalEnrolling by invitationNeuromuscular BlockadeFrance
-
Centre Hospitalier Universitaire Dinant Godinne...CompletedNeuromuscular BlockadeBelgium
-
Seoul National University HospitalCompletedNeuromuscular BlockadeKorea, Republic of
Clinical Trials on Sugammadex
-
University Health Network, TorontoMerck Sharp & Dohme LLCCompletedPosterior Cervical Decompression and FusionCanada
-
Seoul National University HospitalRecruitingPostoperative Residual CurarizationKorea, Republic of
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCRecruitingPostoperative Urinary RetentionUnited States
-
Severance HospitalCompletedAnesthesia Recovery Period, Neuromuscular BlockadeKorea, Republic of
-
University of AthensUnknownSurgical Procedure, UnspecifiedGreece
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedProstate Cancer | Neuromuscular BlockadeItaly
-
Merck Sharp & Dohme LLCCompletedRenal Insufficiency | Renal ImpairmentUnited States
-
Hopital FochCompleted
-
Beijing Tiantan HospitalCompletedSugammadex | Motor Evoked PotentialsChina
-
Merck Sharp & Dohme LLCCompleted